Literature DB >> 16968735

Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III.

Asun Solans1, Andrea Zambrano, Mayra Rodríguez, Antoni Barrientos.   

Abstract

Mitochondrial dysfunction may play an important role in the pathogenic mechanism of Huntington's disease (HD). However, the exact mechanism by which mutated huntingtin could cause bioenergetic dysfunction is still unknown. We have constructed a stable inducible yeast model of HD by expressing a human huntingtin fragment containing a mutant polyglutamine tract of 103Q fused to green fluorescent protein (GFP), and a control expressing a wild-type 25Q domain fused to GFP in a wild-type strain. We showed that in yeast cells expressing 103Q, cell respiration was progressively reduced after 4-6 h of induction with galactose, down to 50% of the control after 10 h of induction. The cell respiration defect results from an alteration in the function and amount of mitochondrial respiratory chain complex II+III, in congruency to data obtained from postmortem brain of HD patients and from toxin models. In our model, the production of reactive oxygen species (ROS) is significantly enhanced in cells expressing 103Q. Quenching of ROS with resveratrol partially prevents the cell respiration defect. Mitochondrial morphology and distribution were also altered in cells expressing 103Q, probably resulting from the interaction of aggregates with portions of the mitochondrial web and from a progressive disruption of the actin cytoskeleton. We propose a mechanism for mitochondrial dysfunction in our yeast model of HD in which the interactions of misfolded/aggregated polyglutamine domains with the mitochondrial and actin networks lead to disturbances in mitochondrial distribution and function and to increase in ROS production. Oxidative damage could preferentially affect the stability and function of enzymes containing iron-sulfur clusters such as complexes II and III. Our yeast model represents a very useful paradigm to study mitochondrial physiology alterations in the pathogenic mechanism of HD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968735     DOI: 10.1093/hmg/ddl248

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  59 in total

Review 1.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

Review 2.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

3.  Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease.

Authors:  Xueyi Li; Antonio Valencia; Ellen Sapp; Nicholas Masso; Jonathan Alexander; Patrick Reeves; Kimberly B Kegel; Neil Aronin; Marian Difiglia
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

4.  Reactive oxygen species act remotely to cause synapse loss in a Drosophila model of developmental mitochondrial encephalopathy.

Authors:  Joshua D Mast; Katharine M H Tomalty; Hannes Vogel; Thomas R Clandinin
Journal:  Development       Date:  2008-07-03       Impact factor: 6.868

5.  Mutant huntingtin disrupts mitochondrial proteostasis by interacting with TIM23.

Authors:  Svitlana Yablonska; Vinitha Ganesan; Lisa M Ferrando; JinHo Kim; Anna Pyzel; Oxana V Baranova; Nicolas K Khattar; Timothy M Larkin; Sergei V Baranov; Ning Chen; Colleen E Strohlein; Donté A Stevens; Xiaomin Wang; Yue-Fang Chang; Mark E Schurdak; Diane L Carlisle; Jonathan S Minden; Robert M Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-25       Impact factor: 11.205

6.  Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts.

Authors:  Luana Naia; I Luísa Ferreira; Teresa Cunha-Oliveira; Ana I Duarte; Márcio Ribeiro; Tatiana R Rosenstock; Mário N Laço; Maria J Ribeiro; Catarina R Oliveira; Frédéric Saudou; Sandrine Humbert; A Cristina Rego
Journal:  Mol Neurobiol       Date:  2014-05-20       Impact factor: 5.590

Review 7.  Mitochondrial matters of the brain: the role in Huntington's disease.

Authors:  C Turner; A H V Schapira
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

8.  Stress-triggered activation of the metalloprotease Oma1 involves its C-terminal region and is important for mitochondrial stress protection in yeast.

Authors:  Iryna Bohovych; Garrett Donaldson; Sara Christianson; Nataliya Zahayko; Oleh Khalimonchuk
Journal:  J Biol Chem       Date:  2014-03-19       Impact factor: 5.157

9.  Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.

Authors:  Jiu-Qiang Wang; Qian Chen; Xianhua Wang; Qiao-Chu Wang; Yun Wang; He-Ping Cheng; Caixia Guo; Qinmiao Sun; Quan Chen; Tie-Shan Tang
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

10.  Chemogenomic and transcriptome analysis identifies mode of action of the chemosensitizing agent CTBT (7-chlorotetrazolo[5,1-c]benzo[1,2,4]triazine).

Authors:  Monika Batova; Vlasta Klobucnikova; Zuzana Oblasova; Juraj Gregan; Pavol Zahradnik; Ivan Hapala; Julius Subik; Christoph Schüller
Journal:  BMC Genomics       Date:  2010-03-04       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.